Zusammenfassung
Wie bereits im Abschnitt 2.1.1 ausgeführt, sind die sedativ-hypnotischen und anxiolytischen Wirkungen der Benzodiazepine schwer voneinander zu trennen. Trotzdem werden einige Derivate bevorzugt als Schlafmittel eingesetzt, die im folgenden besprochen werden sollen. Was allgemeine pharmakokinetische Bemerkungen anbetrifft, sei auf Kapitel 2.1.1 verwiesen (Ochs 1983, Greenblatt et al. 1983). Neben der bioverfügbaren Dosis (F x D) und der individuellen systemischen Clearance (CL) spielt für Wirkintensität und -dauer auch das Verhältnis von Dosierungsintervall (τ) zu Eliminationshalbwertzeit (t1/2) eine wichtige Rolle (s. Scite 16). Da bei Hypnotika t = 24 Stunden ist, wird ein Benzodiazepin mit t1/2 = 12 h oder 48 Stunden beispielsweise um den Faktor 1,33 bzw. 3,44 bei mehrmaliger Gabe kumulieren (siehe Abb. 3.1.1.1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. APA, Washington DC
American Sleep Disorders Association (ASDA) (1990) The international classification of sleep disorders: diagnostic and coding manual. Allen Press, Lawrence
Berman TM, Nino-Murcia G, Roehrs T (1990) Sleep disorders. Take them seriously. Patient Care 23: 85–113
Bixler EO, Kales A, Soldatos C, Kales J, Healey S (1979a) Prevalence of sleep disorders in the Los Angeles Metropolitan Area. J Psychiatry 36: 1257–1262
Bixler EO, Scharf MB, Soldatos CR (1979b) Effects of hypnotic drugs on memory. Life Sci 25: 1379–1388
Buysse DJ, Reyn0olds CF (1990) Insomnia. In: Thorpy MJ (ed) Handbook of sleep disorders. Decker, New York, pp 375–433
Coleman RM (1987) Sleep/wake disorders based on a polysomnographic diagnosis. J Am Med Assoc 247: 997–1003
Cordingly GJ, Dean BC, Harris RI (1984) A double-blind comparison of two benzodiazepine hypnotics, flunitrazepam and triazolam, in general practice. Curr Med Res Opin 8:714–719
Dominguez RA, Goldstein Bjjacobson AF, Steinbook RM (1985) Hypnotic efficacy of a modified triazolodiazepine, brotizolam. Clin Pharmacol Ther 37: 674–679
Fisher RJH, Dean BG (1985) A multi-centre, double-blind trial in general practice. Pharmatherapeutica 4: 231–236
Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: a critival review. J Clin Psychopharmacol 9: 161–172
Goetzke E, Findeisen P, Welbers IB (1983) Efficacy and tolerance: comparative studies with brotizolam and flunitrazepam. Br J Clin Pharmacol 16: 397–402
Hohagen F, Berger M (1989) Differentialdiagnose der Schlafstörungen. In: Hippius H et al. (Hrsg) Psychiatrie für die Praxis, 10. Der gestörte Schlaf. MMV, München, S 19–32
Hohagen F, Berger M (1992) Schlaf und Schlafstörungen im höheren Lebensalter. In: Häfner H, Hennerici M (Hrsg) Psychische Krankheiten und Hirnfunktion im Alter. G Fischer, Stuttgart Jena New York, S 157–169 (Aktuelle Psychiatrie, Bd 8)
Hohagen F, Rink K, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M (1993) Prevalence and treatment of insomnia in general practice. A longitudinal study. Eur Arch Psychiatry Clin Neurosci 242: 329–336
Kales A, Kales J, Bixler EO, Scharf MB, Russek E (1976) Hypnotic efficacy of triazolam: sleep laboratory evaluation of intermediate term effectiveness. J Clin Pharmacol 16: 399–406
Kales A, Soldatos CR, Kales JD (1980) Taking a sleep history. Am Fam Physician 22: 101–108
Kales A, Soldatos CR, Bixler EO, Kales JD (1983) Rebound insomnia and rebound anxiety: a review. Pharmacology 26: 121–137
Karacan I, Thornby JI, Williams RL (1983) Sleep disturbance: a community survey. In: Guilleminault C et al. (eds) Sleep/wake disorders: natural history, epidemiology and long-term evolution. Raven Press, New York, pp 37–60
Kripke DF, Hauri P, Roth T (1987) Sleep evaluation in chronic insomniacs during short-and long-term use of two benzodiazepines, flurazepam and midazolam. Sleep Res 16: 99
Lohse MJ, Müller-Oerlinghausen B (1993) Psychopharmaka. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungs-Report’ 93. G Fischer, Stuttgart Jena, S 343–358
Lugaresi E, Zucconi M, Bixler EO (1987) Epidemiology of sleep disorders. Psychiatr Ann 17: 446–453
Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 42: 225–232
Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Gillin JC (1982) A clinical study of flurazepam. Sleep 5: 350–360
Murri L, Bardi C, Arena R et al. (1983) A comparison between lormetazepam and flunitrazepam in insomniac patients affected by chronic cerebrovascular disorders. Curr Ther Res 35: 113–118
Nicholson ANN (1989) Hypnotics: clinical pharmacology and therapeutics. In: Kryger MH, Roth T, Dement WC (eds) Principals and practice of sleep research. Saunders, Philadelphia London Toronto Montreal Syndney Tokyo, pp 219–227
Parkes JD (1985) Sleep and its disorders. Saunders, London
Partinen M, Kaprio J, Koskenvuo M, Langinvainio H (1983) Sleeping habits, sleep quality and use of sleeping pills: a population study of 31.140 adults in Finland. In: Guilleminaul T et al. (eds) Sleep/wake disorders: natural history, epidemiology and long-term evolution. Raven Press, New York, pp 29–35
Rettig HC, Zuurmond W, VAN Leeuwen L (1988) Quality of sleep and psychomotoric performance after lormetazepam or flunitrazepam: a randomized and double-blind study. Tidschr Ther Gen Ond 13: 141–144
Rickels K, Gingrich R, Morris RJ, Rosenfeld H, Perloff MM, Clark EL, Schilling A (1975) Triazolam in insomniac family practice patients. Clin Pharmacol Ther 18: 315–324
Roehrs T, Vogel G, Roth R (1990) Rebound insomnia: its determinants and significance. Am J Med 88 [Suppl 3A]: 395–425
Scharf MB, Sachais BA, Mayleben DW, Fletcher K, Jennings SW (1990) A polysomnographic comparison of temazepam 15 and 30 mg with triazolam 0,125 and 0,25 mg in chronic insomnia. Curr Ther Res 18: 555–567
Trinder J (1988) Subjective insomnia without objective findings: a pseudo diagnostic classification? Psychol Bull 103: 87–94
Vogel GW, Barker K, Gibbons P, Thurmond A (1976) A comparison of the effects of flurazepam 30 mg and triazolam 0,5 mg on the sleep of insomniacs. J Psychopharmacol 47: 81–86
Weyerer S, Dilling H (1990) Prevalence and treatment of insomnia in the community: results from the upper bavarian field study. Sleep 14: 392–398
Literatur
Bundesverband Der Pharmazeutischen Industrie (1994) Rote Liste 1994. Editio Cantor, Aulendorf/Württemberg
Dorow RG, Scidler J, Schneider HH (1982) A radioreceptor assay to study the affinity of benzodiazepines and their receptor binding activity in human plasma including their active metabolites. Br J Pharmacol 13: 561–565
Gillin JG, Byerley WF (1990) The diagnosis and management of insomnia. N Engl J Med 322: 239–248
Greenblatt DJ (1992) Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 53 [Suppl]: 7–13
Greenblatt DJ, Harmatz JS, Zinny MI, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 317: 722–728
Maczaj M (1993) Pharmacological treatment of insomnia. Drugs 45: 44–55
Mcinnes GT, Bunting EA, Ings RMJ, Robinson J, Ankier SL (1985) Pharmacokinetics and pharmacodynamics following single and repeated nightly administration of loprazolam, a new benzodiazepine hypnotic. Br J Clin Pharmacol 19: 649–656
Mendels J (1990) Criteria for selection of appropriate benzodiazepine hypnotic therapy. J Clin Psychiatry 52 [Suppl]: 42–46
Monolakis J (1990) The use of benzodiazepine for sleep in the elderly. Conn Med 54:691–693
Ray WA, Griffin MR, Schaffner W, Baugh DK (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316: 363–369
Roehrs T, Vogel G, Sterling W, Roth T (1990) Dose effects of temazepam in transient insomnia. Arzneimittelforschung/Drug Res 40: 859–862
Roehrs T, Zorick F, Wittig R, Roth T (1985) Efficacy of a reduced triazolam dose in elderly insomniacs. Neurobiol Aging 6: 293–296
Roehrs TA, Zorick FJ, Wittig RM, Roth T (1986) Dose determinants of rebound insomnia. Br J Clin Pharmacol 22: 143–147
Roth T, Roehrs TA (1991) A review of the safety profiles of benzodiazepine hypnotics. J Clin Psychiatry 52 [Suppl]: 38–41
Roth T, Roehrs TA (1992) Issues in the use of benzodiazepine therapy. J Clin Psychiatry 53 [Suppl]: 14–18
Vogel G(1992) Clinical uses and advantages of low doses of benzodiazepine hypnotics. J Clin Psychiatry 53 [Suppl]: 19–22
Literatur
Adam K, Oswald L (1989) Can a rapidly-eliminated hypnotic cause daytime anxiety? Pharmacopsychiat 22: 115–119
Berzewski H (1986) Risiken und Komplikationen bei der Behandlung des alten Menschen mit Benzodiazepinen. In: Hippius H, Engel RR, Laakmann G (Hrsg) Benzodiazepine — Rückblick und Ausblick. Springer, Berlin Heidelberg New York Tokyo, S 121–130
Bixler EO, Kales A, Soldatos C, KALESJ, Healey S (1979) Prevalence of sleep disorders in the Los Angeles Metropolitan Area. J Psychiatr 136: 1257–1262
Bixler EO, Scharf MB, Soldatos CR (1979) Effects of hypnotic drugs on memory. Life Sci 25: 1379–1388
Bixler EO, Kales A, Manfredi RL, Vgontzas AN, Tyson KL, Kales JD (1991) Next-day memory impairment with triazolam use. The Lancet 337: 827–831
Borbely M (1986) Benzodiazepinhypnotika: Wirkungen und Nachwirkungen von Einzeldosen. In: Hippius H et al. (Hrsg) Benzodiazepine. Springer, Berlin Heidelberg New York Tokyo, S 96–99
Carskadon MA, Scidel WF, Greenblatt DJ (1982) Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep 5: 361–371
Church MW, Johnson LC (1979) Mood and performance of poor sleepers during repeated use with flurazepam. Psychopharmacology 61: 309–316
Einarson TR, Yoder ES (1982) Triazolam psychosis — a syndrome? Drug Intell Clin Pharmacol 16: 330
Gillin JC, Spinweber CL, Johnson LC (1989) Rebound insomnia: a critical review. J Clin Psychopharmacol 9: 161–172
Greenblatt DJ, Harmatz JG, Zinny MA, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 317: 722–728
Hauri P (1982) The sleep disorders, current concepts, scope, 2nd edn. Upjohn, Kalamazoo, pp 31–32
Hohagen F, Grasshoff U, Ellringmann D, Schramm E, Riemann D, Wendt G, Weyerer S, Berger M (1991) The prevalence of insomnia in different age groups and its treatment modalities in general practice. In: Smirne et al. (eds) Sleep and aging. Masson Press, Milano, pp 205–215
Hollister LE (1977) Withdrawal from benzodiazepine therapy. JAMA 237: 1432
Johnson LC, Chernik DA (1982) Sedative hypnotics and human performance. Psychopharmacology 76: 101–113
Kales A, Soldatos CR, Bixler EO, Kales JD (1983a) Rebound insomnia and rebound anxiety: a review. Pharmacology 26: 121–137
Kales A, Soldatos CR, Bixler EO (1983b) Early morning insomnia with rapidly eliminated benzodiazepines. Science 220: 95–97
Kales JD, Kales A (1987) Clinical selection of benzodiazepine hypnotics. Psychiatr Med 2: 229–241
Lader M (1992) Rebound insomnia and newer hypnotics. Psychopharmacology 108:248–255
Luderer HJ (1987) Benzodiazepine — Mißbrauch und Abhängigkeit. Fundam Psychiatr 1: 107–111
Merlotti L, Roehrs T, Zorick FJ, Roth T (1991) Rebound insomnia: duration of use and individual differences. J Clin Psychopharmacol 11: 368–373
Morris HH, Estes ML (1987) Traveler’s amnesia: transient global amnesia secondary to triazolam. JAMA 258: 945–946
Müller WE (1989) Benzodiazepine — Gibt es Unterschiede im Abhängigkeitspotential? Münch Med Wochenschr 131: 385–388
Oswald I, Adam K, Borrow S (1979) The effects of two hypnotics on sleep, subjective feelings and skilled performance. In: Passouant P et al. (eds) Pharmacology of the states of alertness. Pergamon Press, New York
Oswald J, FRENCK, C, Adam K, Gilham J (1982) Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J 284: 860–863
Parkes JD (1985) Sleep and its disorders. Saunders, London
Pevnick J, Jasinski D, Haertzen A (1978) Abrupt withdrawal from therapeutically administered diazepam. Arch Gen Psychiatry 35: 995–998
Preskorn SH, Denner LJ (1977) Benzodiazepines and withdrawal psychosis. JAMA 237: 36–38
Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ III (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316: 363–369
Regstein QR, Reich P (1985) Agitation observed during treatment with newer hypnotic drugs. J Clin Psychiatry 46: 280–283
Rickels K, Case WG, Schweizer EE, Swenson C, Fridman RB (1986) Low-dose dependence in chronic benzodiazepines users: a preliminary report on 119 patients. Psychopharmacol Bull 22: 407–415
Roth T, Hartse KM, Saab PG (1980) The effects of flurazepam, lorazepam, triazolam — on sleep and memory. Psychopharmacology 70: 231–237
Roth T, Zorick F, Sicklesteel J, Stepanski E (1985) Effects of benzodiazepines on sleep and wakefulness. Br J Clin Pharmacol 11: 31–35
Salzman C, Balter M, Ellinwood E, Gallant DM, Gillin JC, Greenblatt DJ, Griffiths R, Hollister LE, Kleber HD, O’brian C, Pincus H, Rikkels K, Sellers E (1990) American Psychiatric Association Task Force on Benzodiazepine dependency, toxicity, and abuse. American Psychiatric Press, Washington
San L, Tato J, Torrens M, Castillo C, Farre M, Cami J (1993) Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug Alcohol Depend 32: 281–286
Schneider-Helmert D (1988) Why low-dose benzodiazepine-dependent insomniacs can’t escape their sleeping pills. Acta Psychiatr Scand 78: 706–711
Schweizer E, Rickels K, Case WG, Greenblatt DJ (1990) Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 47: 908–915
Tyrer P, Murphy S (1987) The place of benzodiazepines in psychiatric practice. Br J Psychiatry 151: 719–723
VAN DER Kroef C (1979) Reactions to triazolam. Lancet ii: 526
Weingartner HJ, Hommer D, Lister RG, Thompson K, Wolkowitz O (1992) Selective effects of triazolam on memory. Psychopharmacology 106: 341–345
Winokur A, Rickels K, Greenblatt DJ (1980) Withdrawal reaction from long-term, lowdosage administration of diazepam. Arch Gen Psychiatry 37: 101–105
Literatur
Abernethy DR, Greenblatt DJ, Divoll M et al. (1983) Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 80: 275–278
Abernethy DR, Greenblatt DJ, Ameer B et al. (1985) Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation. J Pharmacol Exp Ther 234: 345–349
Brockmeyer NH, Mertins L, Klimek K et al. (1990) Comparative effects of rifampin and/or probenecid on the pharmacokinetics of temazepam and nitrazepam. Int J Clin Pharmacol Ther Toxicol 28: 387–393
Dorian P, Sellers EM, Kaplan HL et al. (1985) Triazolam and ethanol interaction: kinetic and dynamic consequences. Clin Pharmacol Ther 37: 558–562
Friedman H, Greenblatt DJ, Burstein ES et al. (1988) Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. J Clin Pharmacol 28: 228–233
Greenblatt DJ, Abernethy DR, Koepke HH, Shader RI (1984 a) Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. J Clin Pharmacol 24: 187–193
Greenblatt DJ, Abernethy DR, Divoll M et al. (1984b) Noninteraction of temazepam and cimetidine. J Pharm Sci 73: 399–401
Grohmann R, Rüther E, Sassim N, Schmidt LG (1989) Adverse effects of clozapine. Psychopharmacology 99: 101–104
Kargas GA, Kargas ST, Bruyere Hj JR et al. (1985) Perinatal mortality due to interaction of diphenhydramine and temazepam. N Engl J Med 313: 1417
Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB et al. (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43: 412–419
Linnoila M, Erwin CW, Brendle A et al. (1981) Effects of alcohol and flunitrazepam on mood and performance in healthy young men. J Clin Pharmacol 21: 430–435
Mattila MAK, Larni HM (1980) Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs 20: 353–374
Phillips JP, Antal EJ, Smith RB (1986) A pharmacokinetic drug interaction between erythromycin and triazolam. J Clin Psychopharmacol 6: 297–299
Pourbaix S, Desager JP, Hulhoven R et al. (1985) Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol 23: 447–451
Sassim N, Grohmann R (1988) Adverse drug reactions with clozapine and simultaneous application of benzodiazepines. Pharmacopsychiatry 21: 306–307
Stoehr GP, Kroboth PD, Juhl RP et al. (1984) Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 36: 683–690
Vanderveen RP, Jirak JL, Peters GR et al. (1990) Effect of ranitidine on the disposition of orally and intravenously administered triazolam. Clin Pharm 10: 539–543
Vatashsky E, Aronson HB (1982) Intravenous flunitrazepam in the prevention of the side effects of succinylcholine. Isr J Med Sci 18: 587–589
Warot D, Bergougnan L, Lamiable D et al. (1987) Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 32: 389–393
Willumeit H-P, Ott H, Neubert W et al. (1984) Alcohol interaction of lormetazepam, mepindolol sulphate and diazepam measured by performance on the driving simulator. Pharmacopsychiatry 17: 36–43
Wilson CM, Robinson FP, Thompson EM et al. (1986) Effect of pretreatment with ranitidine on the hypnotic action of single doses of midazolam, temazepam and zopiclone. A clinical study. Br J Anaesth 58: 483–486
Wright CE, Lasher-Sisson TA, Steenwyk RC et al. (1992) A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12: 103–106
Literatur
Amsoms C, DE Backer-Diereck G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone. Acta Psychiatr Scand 55: 116–122
Bayer AJ, Pathy MS (1985) Requests for hypnotic drugs and placebo response in elderly hospital inpatients. Postgrad Med J 61: 317–320
Buysse DJ, Reynolds CF (1990) Insomnia: In: Thorpy MJ (ed) Handbook of sleep disorders. Decker, New York, pp 375–433
Hauri P (1982) The sleep disorders, current concepts, scope, 2nd edn. Upjohn, Kalamazoo, pp 31–32
Healey ES, Kales A, Lawrence JM, Bixler EO, Chamberline K, Soldatos CR (1981) Onset of insomnia: role of life-stress events. Psychosom Med 43: 439–451
Hohagen F, Grasshoff U, Ellringmann D, Schramm E, Riemann D, Wendt G, Weyerer S, Berger M (1991) The prevalence of insomnia in different age groups and its treatment modalities in general practice. In: Smirne et al. (eds) Sleep and aging. Masson Press, Milano, pp 205–215
Kales A, Caldwell AB, Preston TA (1976) Personality patterns in insomnia: theoretical implications. Arch Gen Psychiatry 33: 1128–1134
Kales A, Caldwell AB, Soldatos CR (1983) Biopsychobehavioral correlates of insomnia. II. Pattern specificity and consistency with the Minnesota Multiphasic Personality Inventory. Psychosom Med 45: 341–356
Parkes JD (1985) Sleep and its discorders. Saunders, London
Riemann D, Schramm E, Dressing H (1995) Schlafstörungen. In: Hautzinger M (Hrsg) Kognitive Verhaltenstherapie bei psychiatrischen Erkrankungen. Quintessenz-Verlag, München
Rüther E, Berger M, Blume H, BORBéLy A, Dietzel M, Dinnendahl V, Doenicke A, Engel R, Fehm L, Gölz J, Gündel L et al. (1992) Epidemiologie, Pathophysiologie, Diagnostik und Therapie von Schlafstörungen. Ergebnisse einer Consensus-Konferenz der Arbeitsgemeinschaft Klinischer Schlafzentren (AKS) und der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). Münch Med Wochenschr 134: 460–466
Schindler L, Hohenberger E (1982) Die verhaltenstherapeutische Behandlung von Schlafstörungen: Status und Perspektiven. Psychol Beitr 24: 549–582
Schönbrunn E, Berger M (1989) Therapie von Schlafstörungen. Münch Med Wochenschr 131: 931–934
Spielman AJ, Saskin P, Thorpy MJ (1987) Treatment of chronic insomnia by restriction of time in bed. Sleep 10: 45–56
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Wien
About this chapter
Cite this chapter
Riederer, P., Laux, G., Pöldinger, W. (1995). Benzodiazepin-Hypnotika. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6593-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6593-5_3
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7357-2
Online ISBN: 978-3-7091-6593-5
eBook Packages: Springer Book Archive